A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
This is a Phase 1/2, multicenter, open-label study conducted in 3 parts (Part A, Part B, and Part C) to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease. Parts A and B are designed to evaluate safety and tolerability and identify the optimal biological dose (OBD) in patients with AATD-associated lung disease (Part A) and/or liver disease (Part B), with optional expansion cohorts to further evaluate a potential OBD. Part C is designed to demonstrate the efficacy and safety of BEAM-302 at the OBD in patients with AATD-associated lung disease with or without liver disease in the pivotal cohort.
• Age 18-70 years.
• Confirmed PiZZ AATD diagnosis.
• Blood total AAT level \<11 μM.
• Willing to discontinue augmentation therapy as required by protocol.
• A postbronchodilator FEV1 ≥40% (Ph 1) of predicted or ≥35% (Ph 2) and an FEV1/FVC \<70% at screening (Ph 1 only).
• Evidence of emphysema on chest imaging.
• Age 18-70 years.
• Confirmed PiZZ AATD diagnosis.
• Clinical diagnosis of AATD-related liver disease along with evidence of METAVIR F1, F2, or F3 liver fibrosis.
• A postbronchodilator FEV1 ≥40% (Phase 1) or ≥35% (Phase 2) of predicted at screening.
• FibroScan ≤12 kPa.
• Age 18-75 years.
• Confirmed PiZZ AATD diagnosis.
• Willing to discontinue augmentation therapy as required by protocol.
• A postbronchodilator FEV1 ≥30% of predicted.
• Evidence of emphysema chest imaging.
• Liver stiffness \<12 kPa.